Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patricia Adams-Graves

Hematology & Oncology Memphis, TN Medical Doctor

NPI 1578529202 CMS profile 252470

880 Madison Ave, Memphis, TN 38103

Open in the dashboard

General payments

$168,159

150 records reported · program years 2019–2025

Research payments

$43,145

Paid to them · 28 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patricia Adams-Graves of Memphis, TN is reported in the CMS Open Payments database as having received $168,159 across 150 general payments and $43,145 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 Research $12,000 10
2024 General $26,400 28
2024 Research $11,975 10
2023 General $5,962 5
2023 Research $18,820 7
2022 General $20,662 15
2022 Research $350 1
2021 General $21,571 18
2020 General $8,074 11
2019 General $85,491 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Adams-Graves
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Patricia Adams-Graves were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Patricia Adams-Graves Hematology & Oncology median Middle half National median
2019 $85,491 $529 $121–$2,516 $163
2020 $8,074 $339 $82–$2,213 $114
2021 $21,571 $263 $49–$1,965 $132
2022 $20,662 $416 $103–$2,395 $149
2023 $5,962 $542 $125–$2,646 $160
2024 $26,400 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $84,805 72 payments
  2. Global Blood Therapeutics, Inc. $44,133 30 payments
  3. Pfizer Inc. $32,310 31 payments
  4. Celgene Corporation $6,394 4 payments
  5. Emmaus Medical, Inc. $179 9 payments
  6. Novo Nordisk Inc $175 2 payments
  7. Abbott Laboratories $144 1 payment
  8. KCI USA, Inc $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $112,784 39 payments
  2. Travel and Lodging $23,522 61 payments
  3. Honoraria $16,940 12 payments
  4. Consulting Fee $8,985 2 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $3,465 1 payment
  6. Food and Beverage $2,463 35 payments
Products named General payments · program years 2019–2025
  1. OXBRYTA Sickle Cell Disease $37,203 26 payments
  2. OXBRYTA Hematology $32,310 31 payments
  3. ADAKVEO $16,572 16 payments
  4. Luspatercept $6,394 4 payments
  5. Endari $179 9 payments
  6. FreeStyle Libre $144 1 payment
  7. RYBELSUS $113 1 payment
  8. NURTEC ODT $100 1 payment
  9. KERRAMAX CARE GENTLE BORDER $18 1 payment
  10. KERRAFOAM SIMPLE BORDER $18 1 payment
  11. Other $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Agios Pharmaceuticals, Inc. $43,145 28 payments

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record